PC-6[illegible]
TOX-5044

005044

Date: January 19, 1983

Subject: EPA File Symbol : 34913 - RL
Sprakil SK-13 Granular Weed Killer

From: Delores J. Graham
TMB/TSS E 1/20/83

To: Robert Taylor
Product Manager (25)

Applicant : SSI Siliconatrics, Inc.
P.O. Box 9276
4711 Piedmont Road
Huntington, WV 25704

Active Ingredients:
Tebuthiuron 1-(5-tert-butyl-1,3,4-
thiadiazol-2yl)-1,3-dimethylurea 1.0%
Diuron 3-(3,4-dichlorophenyl)-1,1-
dimethylurea 3.0%
Inert Ingredients 96.0%

Background: Submitted acute oral, acute dermal, Eye irritation and Primary Dermal Sensitation studies. Studies conducted by Hazelton Laboratories America. Data under accession number 248993. Cite-all-method of support.

Recommendation:
(1) TMB/TSS finds these data acceptable to support conditional registration of this product.

(2) An Acute Inhalation Study was not submitted and one must be submitted and/or cited.

1/5

(3) The appropriate signal word is CAUTION.

(4) For future submissions please note:

(a) In the Eye Irritation Study, 9 animals (6 with treated unwashed eyes and 3 with treated washed eyes) must be used.

(b) In the Primary Dermal Irritation Study, 4 sites (2 abraded and 2 intact) per animal must be used.

Label:
(1) The appropriate precautionary statement for eyes based on the Eye Irritation Study is "Causes eye irritation"

(2) The statement "Keep out of lakes streams ponds" may be revised to read "Do not apply directly to water".

Review:
(1) Acute Oral Toxicity Study: Hazleton Laboratories; Project # 2214-100; November 23, 1982.

Procedure: 5M and 5F Sprague-Dawley rats weighing between 200 and 219 grams received 5000 mg/kg of the test material. Observations were made at one, two and four hours post dose, then twice daily thereafter for fourteen consecutive days. Necropsy performed on all animals.

Results: No mortalities, Clinical signs included slightly depressed to depressed behavior, cough, diarrhea and urine stains. No gross pathology findings noted at necropsy.

Study Classification: Core Guideline Data,

Toxicity Category: III - CAUTION

(2) Acute Dermal Toxicity Study: Hazleton Laboratories; Project # 2214-101; November 22, 1982.

Procedure: 5M and 5F rabbits received 2000 mg/Kg of the test material at intact skin sites under occlusive wrap for 24 hour exposure. Observations made at one and four hours post dose, and twice daily thereafter for 14 consecutive days. Necropsy performed on all animals.

Results: No mortalities. No clinical signs or dermal effects noted. No observable gross pathology noted at necropsy. LD50 was greater than 2000 mg/Kg.

Study Classification: Core Guideline Data.

Toxicity Category: III - CAUTION

(3) Eye Irritation Study: Hazleton Laboratories; Project # 2214-102; November 8, 1982.

Procedure: Six New Zealand rabbits received 0.1g of the test material in one eye each. Observations were made at one, 24, 48 and 72 hours post-treatment.

Results: No corneal opacity, iris irritation, chemosis or discharge present. At 24 hours, 5/6 had slight redness (5/6-1), but had cleared by 48 hours.

Stud. Classification: Core Minimum Data. Six (6 with treated unwashed eyes and 3 with treated washed eyes) must be used.

Toxicity Category: III - CAUTION

(4) Primary Dermal Irritation Study: Hazleton Laboratories; Project # 2214-103; November 10, 1982.

Procedure: Six New Zealand rabbits received 0.5g of the test material at ~~at~~ intact skin sites under occlusive wrap for 4 hour exposure. Observations were made at 1, 24, 48 and 72 hours after exposure.

Results: No erythema, edema or other dermal effects noted throughout the 72 hour ~~other~~ observation period.

Study Classification: Core Minimum Data. 4 sites (2 intact and 2 abraded) per animal must be used.

Toxicity Category: III - CAUTION

DIURON SCIENTIFIC REVIEWS

Page 5 is not included in this copy.

Pages _____ through _____ are not included in this copy.

The material not included contains the following type of information:

___ Identity of product inert ingredients

___ Identity of product impurities

___ Description of the product manufacturing process

___ Description of product quality control procedures

___ Identity of the source of product ingredients

___ Sales or other commercial/financial information

✓ A draft product label

___ The product confidential statement of formula

___ Information about a pending registration action

___ FIFRA registration data

___ The document is a duplicate of page(s) _____

___ The document is not responsive to the request

The information not included is generally considered confidential by product registrants. If you have any questions, please contact the individual who prepared the response to your request.